Physician profile
Michael Heile
NPI 1588628234
$272,220.07
in general payments reported to CMS, 2019-2025
64 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $36K · 2021: $39K · 2022: $53K · 2023: $35K · 2024: $34K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $29K · Consulting Fee: $18K · Food and Beverage: $7,034 · Travel and Lodging: $6,471 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,274.69 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $29,037.50 |
| Consulting Fee | $17,902.50 |
| Food and Beverage | $7,033.88 |
| Travel and Lodging | $6,471.34 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $134,099.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $45,162.38 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbott Laboratories | $23,146.04 | 2019-2024 | Freestyle Libre 3, Infinity |
| Insulet Corporation | $20,934.52 | 2019-2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $17,362.33 | 2019-2023 | Xarelto |
| Roche Diabetes Care Gmbh | $11,286.00 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $9,544.67 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $3,757.19 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $1,092.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $632.56 | 2019-2025 | Korlym |
| Abbvie INC. | $504.04 | 2021-2025 | |
| Amgen INC. | $493.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $344.30 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.46 | 2019-2023 | Cycloset |
| Mannkind Corporation | $258.36 | 2019-2023 | Afrezza |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.80 | 2019-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $240.31 | 2020-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Tandem Diabetes Care, INC. | $229.46 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $218.37 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Amarin Pharma, INC. | $206.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $161.81 | 2019-2025 | |
| Pfizer INC. | $151.82 | 2019-2024 | |
| Beta Bionics, INC. | $142.34 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Esperion Therapeutics, INC. | $136.07 | 2020-2024 | Nexletol |
| Exact Sciences Corporation | $119.08 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $98.17 | 2019-2024 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $97.11 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Medtronic, INC. | $93.87 | 2022-2024 | Minimed 780g |
| Lifescan, INC. | $91.78 | 2019-2023 | |
| Sequel Med Tech, LLC | $91.68 | 2024-2025 | Twiist |
| Takeda Pharmaceuticals U.S.A., INC. | $63.74 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $61.08 | 2023 | Rexulti, Nuedexta |
| Nestle Healthcare Nutrition INC. | $58.55 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $57.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $52.76 | 2020-2025 | Austedo Xr |
| Allergan, INC. | $47.74 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $47.35 | 2019-2025 | Nuzyra |
| Cranial Technologies, INC | $45.50 | 2020-2023 | Doc Band |
| Sanofi Pasteur INC. | $42.17 | 2023 | |
| Valeritas, INC. | $39.46 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $37.10 | 2023-2024 | Baqsimi |
| Avanir Pharmaceuticals, INC. | $33.88 | 2019-2022 | |
| Grifols USA, LLC | $27.76 | 2022-2023 | Prolastin-C Liquid |
| Genentech USA, INC. | $26.24 | 2019-2020 | |
| Horizon Therapeutics Plc | $25.77 | 2019 | |
| Ascensia Diabetes Care US INC. | $25.08 | 2021-2025 | |
| Senseonics, Incorporated | $25.00 | 2019 | |
| Alk-Abello, INC | $23.07 | 2024 | Ragwitek, Odactra, Grastek |
| Viiv Healthcare Company | $21.43 | 2025 | Apretude |
| Gilead Sciences, INC. | $19.35 | 2025 | |
| Sumitomo Pharma America, INC. | $18.52 | 2024 | Gemtesa |
| Eisai INC. | $16.64 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.08 | 2019 | |
| Lundbeck LLC | $15.30 | 2023 | Vyepti |
| Alexion Pharmaceuticals, INC. | $15.22 | 2023 | Strensiq |
| Antares Pharma, INC. | $14.85 | 2020 | |
| Boston Scientific Corporation | $14.29 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.95 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.83 | 2023 | Quviviq |
| Seqirus USA INC | $12.82 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Kowa Pharmaceuticals America, INC. | $12.06 | 2021 | |
| Sun Pharmaceutical Industries INC. | $11.22 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $10.97 | 2019 | |
| Cequr Corporation | $5.01 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Heile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.